Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

URL

https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.17316

Authors

Sylvain Meylan, Françoise Livio, Maryline Foerster, Patrick James Genoud, François Marguet, Gregoire Wuerzner and on behalf of the CHUV COVID Vaccination Center

Published Date

March 25, 2021

Publication

Hypertension

Organization

University of Lausanne (Switzerland)

Medium

document

Topics

adverse events,COVID-19,mRNA,vaccines,vascular system issues